ABC | Volume 113, Nº1, Julho 2019

Artigo Original Kızıltunç et al. Sirtuínas em pacientes com infarto agudo do miocárdio Arq Bras Cardiol. 2019; 113(1):33-39 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 7. Mariani S, Fiore D, Persichetti A, Basciani S, Lubrano C, Poggiogalle E, et al. Circulating SIRT1 Increases After Intragastric Balloon Fat Loss in Obese Patients. Obes Surg. 2016;26(6):1215-20. 8. Doulamis IP, Tzani AI, Konstantopoulos PS, Samanidis G, Georgiopoulos G, Toutouzas KP, et al. A sirtuin 1/MMP2 prognostic index for myocardial infarction in patients with advanced coronary artery disease. Int J Cardiol. 2017 Mar;230:447-53. 9. Winnik S, Auwerx J, Sinclair DA, Matter CM. Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J. 2015;36(48):3404-12. 10. Sosnowska B, Mazidi M, Penson P, Gluba-Brzozka A, Rysz J, Banach M. The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. Atherosclerosis. 2017 Oct;265:275-82. 11. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESCGuidelines for themanagement of acutemyocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST- segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. 12. Patel MR, Mahaffey KW, Armstrong PW, Weaver WD, Tasissa G, Hochman JS, et al. Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). Am J Cardiol. 2005;95(5):614-8. 13. Hori M, Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res. 2009;81(3):457-64. 14. Brown AJ, Mccormick LM, Gajendragadkar PR, Hoole SP, West NE. Initial SYNTAX score predicts major adverse cardiac events after primary percutaneous coronary intervention. Angiology. 2014;65(5):408-12 15. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551-67 16. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentationwith acute coronary syndrome: prospectivemultinational observational study (GRACE). BMJ. 2006;333(7578):1091. 17. MorrowDA, Antman EM, Parsons L, de Lemos JA, Cannon CP, Giugliano RP, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001;286(11):1356-9. 18. Gaziano JM. Global Burden of Cardiovascular Disease. In: Libby P,Bonow RO,Mann DL,Zipes DP (Ed). Braunwald’s Heart Disease, 8 ed. Philedelphi a:Elsevier;2008.p.1-23. 19. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)DevelopedwiththespecialcontributionoftheEuropeanAssociation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016 Sep;252:207-74. 20. Zhang QJ, Wang Z, Chen HZ, Zhou S, Zheng W, Liu G, et al. Endothelium- specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res. 2008;80(2):191-9. 21. Stein S, Lohmann C, Schäfer N, Hofmann J, Rohrer L, Besler C, et al. SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J. 2010;31(18):2301-9. 22. Miranda MX, van Tits LJ, Lohmann C, Arsiwala T, Winnik S, Tailleux A, et al. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. Eur Heart J. 2015;36(1):51-9. 23. Stavrou EX, Fang C, Merkulova A, Alhalabi O, Grobe N, Antoniak S, et al. Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood. 2015;125(4):710-9. 24. Tao R, ColemanMC, Pennington JD, OzdenO, Park SH, Jiang H, et al. Sirt3- mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell. 2010;40(6):893-904. 25. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a- dependent antioxidant defense mechanisms in mice. J Clin Invest. 2009;119(9):2758-71. 26. LappasM. Anti-inflammatory properties of sirtuin 6 in human umbilical vein endothelial cells. Mediators Inflamm. 2012 Oct;2012:597514. 27. Tao R, Xiong X, Depinho RA, Deng CX, Dong XC. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression. J Biol Chem. 2013;288(41):29252-9. 28. Gorenne I, Kumar S, Gray K, Figg N, Yu H, Mercer J, et al. Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis. Circulation. 2013;127(3):386-96. 29. Breitenstein A, Wyss CA, Spescha RD, Franzeck FC, Hof D, Riwanto M, et al. Peripheral blood monocyte Sirt1 expression is reduced in patients with coronary artery disease. PLoS One. 2013;8(1):e53106. 30. Kilic U, Gok O, Bacaksiz A, Izmirli M, Elibol-Can B, Uysal O. SIRT1 gene polymorphismsaffecttheproteinexpression incardiovasculardiseases.PLoS One. 2014;9(2):e90428. 31. Vachharajani VT, Liu T, Wang X, Hoth JJ, Yoza BK, Mccall CE. Sirtuins Link Inflammation and Metabolism. J Immunol Res. 2016 Dec;2016:8167273. 32. Galli M, Van Gool F, Leo O. Sirtuins and inflammation: Friends or foes?. Biochem Pharmacol. 2011;81(5):569-76. 33. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol. 1993;21(2):537-45. 34. CannonRO.Mechanisms,managementand futuredirections forreperfusion injury after acute myocardial infarction. Nat Clin Pract Cardiovasc Med. 2005;2(2):88-94. 35. MurryCE, JenningsRB,ReimerKA.Preconditioningwith ischemia:adelayof lethal cell injury in ischemicmyocardium. Circulation. 1986;74(5):1124-36. 36. HeuschG.Molecularbasisofcardioprotection:signaltransductioninischemic pre-, post-, and remote conditioning. Circ Res. 2015;116(4):674-99. 37. Feng J, Yang Y, Zhou Y, Wang B, Xiong H, Fan C, et al. Bakuchiol attenuates myocardialischemiareperfusioninjurybymaintainingmitochondrialfunction: the role of silent information regulator 1. Apoptosis. 2016;21(5):532-45. 38. Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, et al. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY). 2010;2(12):914-23. 39. Kiziltunc E, Abaci A, Ozkan S, Alsancak Y, Unlu S, Elbeg S, et al. The Relationship between Pre-Infarction Angina and Serum Sphingosine-1- Phosphate Levels. Acta Cardiol Sin. 2014;30(6):546-52. 40. Cho YW, Jang JS, JinHY, Seo JS, Yang TH, KimDK, et al. Relationship between symptom-onset-to-balloon time and long-term mortality in patients with acute myocardial infarction treated with drug-eluting stents. J Cardiol. 2011;58(2):143-50. 39